Key result
Vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide decreased human pancreatic adenocarcinoma cell numbers by 65%, 47%, 37%, and 34% within 24 hours.
Why the study?
Do four peptide hormones (long-acting natriuretic peptide, vessel dilator, kaliuretic peptide, and atrial natriuretic peptide) decrease the number and proliferation of human pancreatic adenocarcinoma cells in culture?
Population
Human pancreatic adenocarcinoma cells in culture
Design
Preclinical
Follow-up
96 h
Authors
Loading...
Hypothesis-generating for natriuretic peptides in pancreatic adenocarcinoma; in vivo studies needed before clinical consideration.
Do four peptide hormones (long-acting natriuretic peptide, vessel dilator, kaliuretic peptide, and atrial natriuretic peptide) decrease the number and proliferation of human pancreatic adenocarcinoma cells in culture?
p-value: p=<0.001
Four peptide hormones, including atrial natriuretic peptide, significantly decrease the number and proliferation of human pancreatic adenocarcinoma cells in vitro via inhibition of DNA synthesis.
Vesely et al. (2003) studied Human pancreatic adenocarcinoma cells. Four peptide hormones (vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, atrial natriuretic peptide) was evaluated on Decrease in the number of human pancreatic adenocarcinoma cells in culture within 24 h (p=<0.001). Vessel dilator, long-acting natriuretic peptide, kaliuretic peptide, and atrial natriuretic peptide decreased human pancreatic adenocarcinoma cell numbers by 65%, 47%, 37%, and 34% within 24 hours.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: